Publication | Open Access

Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model

Cancer ImmunosurveillanceImmunologyTumor ImmunityImmune Checkpoint InhibitorAnti-pd-l1 Prolongs SurvivalImmunotherapyMedicineCell BiologyTumor MicroenvironmentOvarian CancerTriggers T Cell